Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

• Main Authors: A. Hochhaus, G. Saglio, T. P. Hughes, R. A. Larson, D. W. Kim, S. Issaragrisil, P. D. Le Coutre, G. Etienne, P. E. Dorlhiac-Llacer, R. E. Clark, I. W. Flinn, H. Nakamae, B. Donohue, W. Deng, D. Dalal, H. D. Menssen, H. M. Kantarjian
• Other Authors: Universitatsklinikum Jena und Medizinische Fakultat
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/43066
• Institution: Mahidol University

© 2016 Macmillan Publishers Limited. In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in...